Monoclonal antibody-ricin hybrids as a treatment of murine graft

Details Monoclonal antibody-ricin hybrids as a treatment of murine graft Monoclonal antibody-ricin hybrids as a treatment of murine graft

1982-02-19

1984-04-03

Rosen, Sam

Drug, bio-affecting and body treating compositions

Lymphokine

424101, 604 28, A61K 3900

Patent

active

044407475

ABSTRACT:
The receptor specificity of toxins can be altered by coupling the intact toxin to monoclonal antibodies directed to the cell surface antigen Thy 1.2. Monoclonal antibody Thy 1.2-ricin (or ricin A chain) is a pretreatment reagent used to eliminate graft-versus-host disease (GVHD) in bone marrow transplants.

REFERENCES:
patent: 4340535 (1982-07-01), Voisin et al.
patent: 4359457 (1982-11-01), Neville
Letarte, Chem. Abs., vol. 93, 1980, Ab. No. 93:202498z.
Oeltmann Chem. Abs., vol. 95, 1981, Ab. No. 95:78306k.
Thorpe, Chem. Abs., vol. 95, 1981, Ab. No. 95:22810c.
Pau, Chem. Abs., vol. 94, 1981, Ab. No. 94:132084j.
Cotmore, Eur. J. Immunol., vol. 11, 1981, pp. 597-603.
Youle, PNAS, vol. 77, No. 9, Sep. 1980, pp. 5483-5486.
Neville, Biochem. Soc. London Trans., vol. 8, No. 6, 1980, pp. 692-693.
Moulten, Proc. Amer. Asso. Cancer Res., Abs., vol. 15, 1974, p. 24, Ab. No. 94.
Jansen Immunobiol., vol. 157, No. 3, 1980, pp. 229-230.
Saxena, Immunol. Communications, vol. 9, No. 4, 1980, pp. 371-378.

Affiliated with

Also associated with

Rating

Monoclonal antibody-ricin hybrids as a treatment of murine graft does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Monoclonal antibody-ricin hybrids as a treatment of murine graft, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Monoclonal antibody-ricin hybrids as a treatment of murine graft will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-666985